{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:52:41Z","timestamp":1791298361475,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA108671"],"award-info":[{"award-number":["P01 CA108671"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kymera Therapeutics Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03163-2","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:02:56Z","timestamp":1791291776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem\/progenitor cells"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4191-4787","authenticated-orcid":false,"given":"Min","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Chutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyoti","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6732","authenticated-orcid":false,"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"3163_CR1","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med"},{"key":"3163_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"3163_CR3","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472\u20136.","journal-title":"Blood"},{"key":"3163_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062\u20139.","journal-title":"Blood"},{"key":"3163_CR5","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","volume":"4","author":"P Bose","year":"2020","unstructured":"Bose P, Verstovsek S. JAK Inhibition for the treatment of myelofibrosis: limitations and future perspectives. Hemasphere. 2020;4:e424.","journal-title":"Hemasphere"},{"key":"3163_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MOH.0000000000000406","volume":"25","author":"N Szuber","year":"2018","unstructured":"Szuber N, Tefferi A. Driver mutations in primary myelofibrosis and their implications. Curr Opin Hematol. 2018;25:129\u201335.","journal-title":"Curr Opin Hematol"},{"key":"3163_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000450956","volume":"25","author":"SH Alshemmari","year":"2016","unstructured":"Alshemmari SH, Rajan R, Emadi A. Molecular pathogenesis and clinical significance of driver mutations in primary myelofibrosis: a review. Med Princ Pract. 2016;25:501\u20139.","journal-title":"Med Princ Pract"},{"key":"3163_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/asheducation-2006.1.233","volume":"510","author":"RL Levine","year":"2006","unstructured":"Levine RL, Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2006;510:233\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3163_CR9","doi-asserted-by":"publisher","first-page":"e35801","DOI":"10.1002\/cncr.35801","volume":"131","author":"M Breccia","year":"2025","unstructured":"Breccia M, Palandri F, Martelli M, Mendicino F, Malato A, Palumbo GA, et al. Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI). Cancer. 2025;131:e35801.","journal-title":"Cancer"},{"key":"3163_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14796694.2024.2440255","volume":"21","author":"C Harrison","year":"2025","unstructured":"Harrison C, Kiladjian JJ, Vannucchi AM, Mesa RA. Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary. Future Oncol. 2025;21:617\u201325.","journal-title":"Future Oncol"},{"key":"3163_CR11","doi-asserted-by":"publisher","first-page":"e70316","DOI":"10.1002\/hem3.70316","volume":"10","author":"B Mora","year":"2026","unstructured":"Mora B, Franchi M, Margotto L, Leoni O, D\u2019Ippoliti D, Carloni E, et al. Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis. Hemasphere. 2026;10:e70316.","journal-title":"Hemasphere"},{"key":"3163_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","volume":"130","author":"KJ Newberry","year":"2017","unstructured":"Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130:1125\u201331.","journal-title":"Blood"},{"key":"3163_CR13","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2011.313","volume":"31","author":"M Nakatake","year":"2012","unstructured":"Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31:1323\u201333.","journal-title":"Oncogene"},{"key":"3163_CR14","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","volume":"88","author":"E Feinstein","year":"1991","unstructured":"Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA. 1991;88:6293\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3163_CR15","first-page":"1","volume":"14","author":"T Hernandez-Boussard","year":"1999","unstructured":"Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat. 1999;14:1\u20138.","journal-title":"International Agency for Research on Cancer. Hum Mutat"},{"key":"3163_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ajh.10188","volume":"71","author":"S Tsurumi","year":"2002","unstructured":"Tsurumi S, Nakamura Y, Maki K, Omine M, Fujita K, Okamura T, et al. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol. 2002;71:131\u20133.","journal-title":"Am J Hematol"},{"key":"3163_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364:488\u201390.","journal-title":"N Engl J Med"},{"key":"3163_CR18","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","volume":"2","author":"BK Marcellino","year":"2018","unstructured":"Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, et al. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018;2:3581\u20139.","journal-title":"Blood Adv"},{"key":"3163_CR19","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.2147\/OTT.S172315","volume":"12","author":"A Khurana","year":"2019","unstructured":"Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Onco Targets Ther. 2019;12:2903\u201310.","journal-title":"Onco Targets Ther"},{"key":"3163_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","volume":"76","author":"W Wang","year":"2024","unstructured":"Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, et al. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024;76:414\u201353.","journal-title":"Pharmacol Rev"},{"key":"3163_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00823-x","volume":"9","author":"V Khanna","year":"2025","unstructured":"Khanna V, Eslami G, Reyes R, Diep R, Fernandez-Pol S, Stehr H, et al. MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis. NPJ Precis Oncol. 2025;9:34.","journal-title":"NPJ Precis Oncol"},{"key":"3163_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","volume":"13","author":"CM Adams","year":"2023","unstructured":"Adams CM, Mitra R, Xiao Y, Michener P, Palazzo J, Chao A, et al. Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer. Cancer Discov. 2023;13:1210\u201329.","journal-title":"Cancer Discov"},{"key":"3163_CR23","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","volume":"34","author":"M Konopleva","year":"2020","unstructured":"Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, et al. MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020;34:2858\u201374.","journal-title":"Leukemia"},{"key":"3163_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41408-023-00871-1","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, et al. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023;13:101.","journal-title":"Blood Cancer J"},{"key":"3163_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70028","volume":"13","author":"CD DiNardo","year":"2024","unstructured":"DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, et al. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med. 2024;13:e70028.","journal-title":"Cancer Med"},{"key":"3163_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","volume":"124","author":"M Lu","year":"2014","unstructured":"Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells. Blood. 2014;124:771\u20139.","journal-title":"Blood"},{"key":"3163_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41375-021-01446-4","volume":"36","author":"M Lu","year":"2022","unstructured":"Lu M, Xia L, Elmansy N, Clementelli C, Tremblay D, Hoffman R. Combined drug targeting of p53-dependent and -independent pathways depletes myelofibrosis hematopoietic stem\/progenitor cells. Leukemia. 2022;36:733\u201345.","journal-title":"Leukemia"},{"key":"3163_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood.2018893545","volume":"134","author":"J Mascarenhas","year":"2019","unstructured":"Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134:525\u201333.","journal-title":"Blood"},{"key":"3163_CR29","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, et al. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed\/refractory myelofibrosis. Future Oncol 2022;18:4059\u201369.","DOI":"10.2217\/fon-2022-0901"},{"key":"3163_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106222","volume":"86","author":"L Pi","year":"2019","unstructured":"Pi L, Rooprai J, Allan DS, Atkins H, Bredeson C, Fulcher AJ, et al. Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: a systematic review of the literature. Leuk Res. 2019;86:106222.","journal-title":"Leuk Res"},{"key":"3163_CR31","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-25-0762","volume":"31","author":"EE Dumbrava","year":"2025","unstructured":"Dumbrava EE, Stinchcombe TE, Gounder M, Cote GM, Hanna GJ, Sumrall B, et al. Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: preclinical and phase ii clinical trial results. Clin Cancer Res. 2025;31:4255\u201364.","journal-title":"Clin Cancer Res"},{"key":"3163_CR32","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.22.01285","volume":"41","author":"MM Gounder","year":"2023","unstructured":"Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, et al. A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas. J Clin Oncol. 2023;41:1714\u201324.","journal-title":"J Clin Oncol"},{"key":"3163_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03356-8","volume":"24","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zhang Q, Li Z, Zhang H. MDM2: current research status and prospects of tumor treatment. Cancer Cell Int. 2024;24:170.","journal-title":"Cancer Cell Int"},{"key":"3163_CR34","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/jmcb\/mjz075","volume":"11","author":"G Sanz","year":"2019","unstructured":"Sanz G, Singh M, Peuget S, Selivanova G. Inhibition of p53 inhibitors: progress, challenges and perspectives. J Mol Cell Biol. 2019;11:586\u201399.","journal-title":"J Mol Cell Biol"},{"key":"3163_CR35","doi-asserted-by":"crossref","unstructured":"Al-Ali HK, Heidel ST, Palandri F, Heidel FH. MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms. Leukemia. 2026;40:1111\u20131121.","DOI":"10.1038\/s41375-026-02975-6"},{"key":"3163_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393:556\u201368.","journal-title":"N Engl J Med"},{"key":"3163_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70132","volume":"131","author":"YA Anaya","year":"2025","unstructured":"Anaya YA, Barragan M, Bracho RP, Shaham SH, Bandyopadhyay D, George E, et al. Proteolysis-targeting chimeras in cancer therapy: targeted protein degradation for next-generation treatment. Cancer. 2025;131:e70132.","journal-title":"Cancer"},{"key":"3163_CR38","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/1878-0261.70034","volume":"19","author":"N Herbel","year":"2025","unstructured":"Herbel N, Postel-Vinay S. Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours? Mol Oncol. 2025;19:2461\u20137.","journal-title":"Mol Oncol"},{"key":"3163_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","volume":"20","author":"D Chirnomas","year":"2023","unstructured":"Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic\u2014a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20:265\u201378.","journal-title":"Nat Rev Clin Oncol"},{"key":"3163_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/1535-7163.MCT-24-0306","volume":"24","author":"YK Chutake","year":"2025","unstructured":"Chutake YK, Mayo MF, Dumont N, Filiatrault J, Breitkopf SB, Cho P, et al. KT-253, a novel MDM2 degrader and p53 stabilizer, has superior potency and efficacy than MDM2 small-molecule inhibitors. Mol Cancer Ther. 2025;24:497\u2013510.","journal-title":"Mol Cancer Ther"},{"key":"3163_CR41","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1158\/2159-8290.CD-23-0229","volume":"13","author":"S Peuget","year":"2023","unstructured":"Peuget S, Selivanova G. MDM2-PROTAC versus MDM2 inhibitors: beyond p53 reactivation. Cancer Discov. 2023;13:1043\u20135.","journal-title":"Cancer Discov"},{"key":"3163_CR42","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","volume":"20","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, et al. VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer. Future Oncol. 2024;20:2447\u201355.","journal-title":"Future Oncol"},{"key":"3163_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/1078-0432.CCR-25-0471","volume":"32","author":"S Nayak","year":"2026","unstructured":"Nayak S, Norris JD, Ammirante M, Rychak E, Wardell SE, Liao D, et al. Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader and antagonist, for the treatment of advanced prostate cancer. Clin Cancer Res. 2026;32:224\u201341.","journal-title":"Clin Cancer Res"},{"key":"3163_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","volume":"36","author":"DE Rathkopf","year":"2025","unstructured":"Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36:76\u201388.","journal-title":"Ann Oncol"},{"key":"3163_CR45","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","volume":"2016","author":"F Passamonti","year":"2016","unstructured":"Passamonti F, Maffioli M. Update from the latest WHO classification of MPNs: a user\u2019s manual. Hematology Am Soc Hematol Educ Program. 2016;2016:534\u201342.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3163_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<344::AID-CNCR14>3.0.CO;2-6","volume":"88","author":"W Fiedler","year":"2000","unstructured":"Fiedler W, Henke RP, Ergun S, Schumacher U, Gehling UM, Vohwinkel G, et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report. Cancer. 2000;88:344\u201351.","journal-title":"Cancer"},{"key":"3163_CR47","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/sj.leu.2401608","volume":"14","author":"K Uozumi","year":"2000","unstructured":"Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S, et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia. 2000;14:142\u201352.","journal-title":"Leukemia"},{"key":"3163_CR48","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","volume":"2","author":"CJ McNamara","year":"2018","unstructured":"McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Adv. 2018;2:2658\u201371.","journal-title":"Blood Adv"},{"key":"3163_CR49","first-page":"483","volume":"144","author":"JO Mascarenhas","year":"2024","unstructured":"Mascarenhas JO, Bose P, Hou H-A, Homenda W, Ross D, Mohan SR, et al. Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed\/refractory myelofibrosis. Blood 2024. 2024;144:483.","journal-title":"Blood 2024"},{"key":"3163_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.101790","volume":"31","author":"AM Alaseem","year":"2023","unstructured":"Alaseem AM. Advancements in MDM2 inhibition: clinical and pre-clinical investigations of combination therapeutic regimens. Saudi Pharm J. 2023;31:101790.","journal-title":"Saudi Pharm J"},{"key":"3163_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116506","volume":"272","author":"H Li","year":"2024","unstructured":"Li H, Cai X, Yang X, Zhang X. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy. Eur J Med Chem. 2024;272:116506.","journal-title":"Eur J Med Chem"},{"key":"3163_CR52","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.18632\/oncotarget.719","volume":"3","author":"M Lu","year":"2012","unstructured":"Lu M, Hoffman R. p53 as a target in myeloproliferative neoplasms. Oncotarget. 2012;3:1052\u20133.","journal-title":"Oncotarget"},{"key":"3163_CR53","first-page":"913","volume":"21","author":"JD Down","year":"1993","unstructured":"Down JD, Ploemacher RE. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol. 1993;21:913\u201321.","journal-title":"Exp Hematol"},{"key":"3163_CR54","first-page":"5470","volume":"60","author":"GR Westerhof","year":"2000","unstructured":"Westerhof GR, Ploemacher RE, Boudewijn A, Blokland I, Dillingh JH, McGown AT, et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res. 2000;60:5470\u20138.","journal-title":"Cancer Res"},{"key":"3163_CR55","first-page":"66","volume":"26","author":"M Balzarotti","year":"1999","unstructured":"Balzarotti M, Grisanti S, Granzow K, Saladini A, Sala A, Nozza A, et al. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Semin Oncol. 1999;26:66\u201371.","journal-title":"Semin Oncol"},{"key":"3163_CR56","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1182\/blood.V88.6.1944.bloodjournal8861944","volume":"88","author":"W Terpstra","year":"1996","unstructured":"Terpstra W, Ploemacher RE, Prins A, van Lom K, Pouwels K, Wognum AW, et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood. 1996;88:1944\u201350.","journal-title":"Blood"},{"key":"3163_CR57","first-page":"3084","volume":"42","author":"MRR-u-H Khawaja","year":"2024","unstructured":"Khawaja MRR-u-H, Naqash AR, Schneider R, Shastri A, Stahl M, Moser JC, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed\/refractory (R\/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). J Clin Oncol 2024. 2024;42:3084.","journal-title":"J Clin Oncol 2024"},{"key":"3163_CR58","first-page":"1395","volume":"34","author":"SK Peirce","year":"2009","unstructured":"Peirce SK, Findley HW. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol. 2009;34:1395\u2013402.","journal-title":"Int J Oncol"},{"key":"3163_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10495-010-0538-0","volume":"16","author":"RM Ray","year":"2011","unstructured":"Ray RM, Bhattacharya S, Johnson LR. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis. 2011;16:35\u201344.","journal-title":"Apoptosis"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03163-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:29:28Z","timestamp":1791296968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03163-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":59,"alternative-id":["3163"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03163-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Hoffman received research support from Kymera Therapeutics Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}